CNS Pharmaceuticals expects cash to fund operations into 4Q23

s of June 30, 2023, the Company had cash of approximately $4.3 million and working capital of approximately $2.1 million. The Company’s current expectation is that the cash on hand is sufficient to fund operations into the fourth quarter of 2023, through the topline data readout for the Berubicin potentially pivotal study. The timing and costs of clinical trials are difficult to predict and trial plans and timing of milestones may change in response to evolving circumstances and as such the foregoing estimates may prove to be inaccurate.